Maxcyte Stock EBITDA
| MXCT Stock | USD 3.55 0.03 0.85% |
MaxCyte fundamentals help investors to digest information that contributes to MaxCyte's financial success or failures. It also enables traders to predict the movement of MaxCyte Stock. The fundamental analysis module provides a way to measure MaxCyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MaxCyte stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -44.1 M | -41.9 M |
MaxCyte | EBITDA |
MaxCyte Company EBITDA Analysis
MaxCyte's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current MaxCyte EBITDA | (44.13 M) |
Most of MaxCyte's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MaxCyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
MaxCyte EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for MaxCyte is extremely important. It helps to project a fair market value of MaxCyte Stock properly, considering its historical fundamentals such as EBITDA. Since MaxCyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MaxCyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MaxCyte's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
MaxCyte Ebitda
Ebitda |
|
According to the company disclosure, MaxCyte reported earnings before interest,tax, depreciation and amortization of (44.13 Million). This is 105.03% lower than that of the Health Care Equipment & Supplies sector and 106.87% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.13% higher than that of the company.
MaxCyte EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MaxCyte's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MaxCyte could also be used in its relative valuation, which is a method of valuing MaxCyte by comparing valuation metrics of similar companies.MaxCyte is currently under evaluation in ebitda category among its peers.
MaxCyte ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MaxCyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MaxCyte's managers, analysts, and investors.Environmental | Governance | Social |
MaxCyte Institutional Holders
Institutional Holdings refers to the ownership stake in MaxCyte that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of MaxCyte's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing MaxCyte's value.| Shares | Portolan Capital Management, Llc | 2024-06-30 | 1.7 M | Swedbank Ab | 2024-09-30 | 1.6 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.4 M | Chevy Chase Trust Holdings, Inc. | 2024-09-30 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | Ameriprise Financial Inc | 2024-06-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 860.3 K | Silvercrest Asset Management Group Llc | 2024-06-30 | 708.2 K | Centerbook Partners Lp | 2024-09-30 | 585.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 9.3 M | Cadian Capital Management Lp | 2024-09-30 | 8.2 M |
MaxCyte Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (1.72) % | ||||
| Current Valuation | 232.21 M | ||||
| Shares Outstanding | 105.48 M | ||||
| Shares Owned By Insiders | 1.49 % | ||||
| Shares Owned By Institutions | 70.57 % | ||||
| Number Of Shares Shorted | 3.32 M | ||||
| Price To Book | 1.76 X | ||||
| Price To Sales | 8.21 X | ||||
| Revenue | 41.29 M | ||||
| Gross Profit | 39.16 M | ||||
| EBITDA | (44.13 M) | ||||
| Net Income | (37.92 M) | ||||
| Cash And Equivalents | 240.89 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 18.74 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 14.24 X | ||||
| Book Value Per Share | 2.03 X | ||||
| Cash Flow From Operations | (21.69 M) | ||||
| Short Ratio | 6.72 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 9.25 | ||||
| Number Of Employees | 143 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 374.46 M | ||||
| Total Asset | 268.27 M | ||||
| Retained Earnings | (175.8 M) | ||||
| Working Capital | 172.34 M | ||||
| Net Asset | 268.27 M |
About MaxCyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MaxCyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MaxCyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MaxCyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.